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Chronic infection with hepatitis B virus (HBV) is a major risk factor
for hepatocellular carcinoma. The HBV X protein (HBx) is thought to
have oncogenic potential, although the molecular mechanism
remains obscure. Pathological roles of HBx in the carcinogenic
process have been examined using rodent systems and no report is
available on the oncogenic roles of HBx in human cells in vitro.
We therefore examined the effect of HBx on immortalization and
transformation in human primary cells. We found that HBx could
overcome active RAS-induced senescence in human immortalized
cells and that these cells could form colonies in soft agar and tumors
in nude mice. HBx alone, however, could contribute to neither
immortalization nor transformation of these cells. In a population
doubling analysis, an N-terminal truncated mutant of HBx, HBx-D1
(amino acids 51–154), which harbors the coactivation domain, could
overcome active RAS-induced cellular senescence, but these cells
failed to exhibit colonigenic and tumorigenic abilities, probably due
to the low expression level of the protein. By scanning a HBx expression
library of the clustered-alanine substitution mutants, the N-terminal
domain was found to be critical for overcoming active RAS-induced
senescence by stabilizing full-length HBx. These results strongly
suggest that HBx can contribute to carcinogenesis by overcoming active
oncogene-induced senescence. (Cancer Sci 2007; 98: 1540–1548)
Chronic infection with HBV is a major risk factor for HCCworldwide. HBV belongs to the Hepadnavirus family. Its
genome is a 3.2-kb, circular, partially double-stranded DNA
molecule with four overlapping open reading frames: PC-C,
PS-S, P and X.(1) The HBV genome, which is converted to
covalently closed circular DNA in the nucleus after infection,
serves as the template for transcription, generating the four viral
transcripts that encode the HBV core and polymerase polypeptides,
the large surface antigen polypeptide, the middle and major
surface antigen polypeptides, and the HBx polypeptide. HBV
replicates by reverse transcription of viral pregenomic 3.5-kb
RNA using the HBV polymerase that catalyzes RNA-dependent
DNA synthesis and DNA-dependent DNA synthesis.(1,2) It is
converted into the 3.2-kb partially double-stranded genomic
DNA inside the viral capsid.
The critical role of HBV chronic infection in HCC has been
well established etiologically, whereas the mechanism by which
HBV causes transformation of hepatocytes remains unclear.(3–5)
HBx has long been suspected of playing a positive role in
hepatocarcinogenesis, as avian hepadnaviruses missing the X
open reading frame seem not to be associated with HCC. HBx
consists of 154 aa and is a multifunctional regulator that modu-
lates many host cell functions through its interactions with a
variety of host factors.(5) HBx consists of both a negative
regulatory domain(6) and a coactivation domain that is required
for the augmentation of virus and host genes.(7,8) HBx was
reported to transform rodent immortal cells in vitro,(9,10) and a
high incidence of HCC has been reported in transgenic mice
overexpressing HBx.(11,12) However, the functional role of HBx
in the transformation is still controversial. Some independent
groups proposed collaborating roles of HBx in the hepatocarci-
nogenic process.(13–15) Although these reports are informative, all
were experimentally assessed in rodent systems. Because mouse
and human primary cells have different telomere biology,(16)
DNA damage check point control mechanisms and cell cycle
progression,(17,18) developing a human system to address the
functional role of HBx is critically important. Here we report
that we established human fibroblast cells stably expressing
HBx protein and analyzed the effects of HBx expression on
the ability to confer an immortal phenotype and tumorigenic
potential.
Materials and Methods
Retroviral vectors. All constructs for the expression of HBx
(subtype adr) proteins, pNKF-HBx (aa 1–154), pNKF-HBx-D1
(aa 1–50) and pNKF-HBx-D5 (aa 51–154) have been described
previously.(8) The retrovirus vectors pBabe-puro, hygro, puro-H-
RASV12 hygro-hTERT and pWZL-blast were kindly provided by
W. C. Hahn (Dana-Farber Cancer Institute, Harvard).(19,20) To
construct pBabe-blast, the blasticidin S cDNA of pWZL-blast
was used as a template to amplify the PCR products of blasticidin
S with the primer set of AAGCTTACCATGGCCAAGCCTTTGT
and ATCGATTTAGCCCTCCCACACATAA, generating an
artificial HindIII site at the 5-end and a ClaI site at the 3′-end,
respectively. The HBx cDNA of pNKF-HBx was used as a template
to amplify the PCR products of HBx with a primer set of
TGATCAATGGACTACAAAGACGAT and CTCGAGAGAT-
CTTTAATTAATTAA, generating an artificial FbaI site at the
5-end and an XhoI site at the 3′-end, respectively. The PCR
products were digested and inserted into the BamHI and SalI
sites of the pBabe-blast vector. The EcoRI and BglII fragments
of HBx-D1 and HBx-D5 from pNKF-HBx-D1 and pNKF-HBx-
D5 were, respectively, inserted into the EcoRI and BglII sites of
the pBabe-blast-HBx vectors. An alanine scanning method was
applied to construct a series of HBx clustered alanine substitution
mutants (designated ‘cm’) by site-directed mutagenesis. The
mutagenesis was carried out using a splicing PCR method with all
of the mutated oligonucleotide primer sets. The target sequence
of seven aa residues was changed to AAASAAA, and all of the
HBx-encoding DNA fragments bearing the clustered mutations
were introduced into the EcoRI and BamHI sites of pNKFLAG,
generating the pNKF-Xcm1 to pNKF-Xcm21 constructs. The
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EcoRI and BglII fragments of HBx-cm1 to HBx-cm21 from
pNKF-Xcm1 to pNKF-Xcm21 were, respectively, inserted into
the EcoRI and BglII sites of the pBabe-blast-HBx vectors. All of
the constructs were sequenced by the dideoxy method using
the Taq sequencing primer kit and a DNA sequencer (370A;
Applied Biosystems).
Virus production and cell lines. Amphotropic retroviruses were
produced by transfection of the 293T producer cell line with a
retroviral vector and a vector encoding replication-defective
helper viruses, pCL-Ampho (Imgenex), using FuGENE 6 transfection
reagent (Roche Applied Science) according to the manu-
facturer’s recommendations. Two days after the transfection,
culture supernatants were collected, filtered, supplemented with
4 µg/mL polybrene, and used for infection. Two days after
the infection, drug selection of infected cells was started, and
the selected populations were used in all of the experiments.
Infected cell populations were selected in puromycin
(1.0 µg/mL), blasticidin S (4 µg/mL) and hygromycin
(80 µg/mL) for up to 2 weeks.
Cell culture. Human lung fibroblasts (TIG3) from the
Japanese Collection of Research Bioresources were maintained
in DMEM with 10% heat-inactivated fetal bovine serum (JRH
Biosciences). Human foreskin fibroblasts, BJ and BJ-hTERT-
LT-ST-H-RASV12 cells were maintained as described previously.(19)
These human fibroblasts were not clonal and were maintained as
populations. BJ cells and TIG3 cells have a finite lifespan, and
were used at PD between 25 and 35. PD were determined using
the formula:
PD = Log(Nf/Ni)/Log2,
where Nf = the number of cells counted and Ni = the number of
cells seeded. Comparisons of means and standard deviations
were carried out using the unpaired t-test.
Western blot analysis. Cells were harvested, washed with
phosphate-buffered saline (–), and sonicated in a lysis buffer (50 mM
Tris-HCl [pH 7.4], 200 mM NaCl, 1 mM ethylenediaminetetra-
acetic acid, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride,
10 µg/mL leupeptin, 10 µg/mL aprotinin and 10 µg/mL
dithiothreitol). Total lysates were fractionated by SDS-PAGE,
transferred onto nitrocellulose membranes and subjected to
western blot analysis with antibodies. Anti-FLAG M2 antibody
and anti-β-actin antibody were from Sigma. Anti-RAS antibody
F-235 (sc-29), anti-p53 antibody DO-1 (sc-126) and anti-p21
antibody F-5 (sc-6246) were from Santa Cruz. Anti-p16 antibody
was from BD PharMingen. The proteins were visualized by
enhanced chemiluminescence according to the manufacturer’s
instructions (Amersham).
Analysis of senescence. SA-β-Gal staining was carried out
using the Senescence Detection Kit (Oncogene) as instructed
by the manufacturer. For each sample, at least 200 cells were
counted in randomly chosen fields.
Telomerase activity assays. Total lysates of cells were sub-
jected to the telomerase repeat amplification protocol using
a TRAPEZE kit (Intergen) according to the manufacturer’s
instructions.
Soft-agar colony formation assays. Soft-agar growth assays were
carried out as described previously.(19) At the time of plating in
soft agar, cultures were trypsinized and counted, and 5 × 103 or
5 × 104 total cells were mixed with 1.5 mL of 0.35% Noble
agar-DMEM (top layer) and then poured on top of 5 mL of
solidified 0.7% Noble agar-DMEM (bottom layer) in 6-cm-
diameter dishes. After 3 weeks, colonies were counted, and
pictures were taken.
Tumorigenicity assays. A total of 1 × 106 cells were resuspended
in 50 µL Matrigel solution (BD Matrigel Basement Membrane
Matrix HC; BD Biosciences) and immediately injected
subcutaneously into 8-week-old female nude mice (BALB/
cAnNCrl-nu BR). 2-D tumor sizes were measured once a week.
The tumor volume (mm3) was calculated using the formula
(length × width2)/2.(21)
Results
Effect of HBx on cellular senescence of human primary cells.
During immortalization, human cells differ from rodent cells
in the regulation of telomere length(22,23) and cell cycle
checkpoints.(24,25) Human cells must bypass two barriers to
become immortalized: replicative senescence and crisis.
Replicative senescence is characterized by an irreversible
growth arrest but continued metabolic activity.(26) Crisis is
characterized by widespread cell death.(26,27) By the introduction
of hTERT, human primary cells avoid these two barriers and
can become immortalized.(28–30)
It is possible that HBx contributes to the immortalization
process of human primary cells, but not to the cellular transfor-
mation process. If so, it may facilitate cellular transformation
indirectly by overcoming two crises, M1 and M2. To study
whether this does facilitate cellular transformation, it is best to
use human primary hepatocytes as HBV is a hepatotropic virus.
However, human primary hepatocytes are almost impossible
to obtain for such an experimental approach. HBx exhibits its
transactivation function not only in hepatoma cell lines but also
in various carcinoma and sarcoma cell lines. Under these situa-
tions, we addressed whether HBx contributes to the immortaliza-
tion of human primary fibroblasts, BJ cells and TIG3 cells that
have been well studied for cellular senescence and immortaliza-
tion. We used hTERT-introduced BJ and TIG3 cells for positive
controls of immortal cells.
The human primary fibroblasts, BJ cells and TIG3 cells were
infected with the HBx-expression retroviruses and cultured in
the presence of the selection drug, blastcidin S. The drug-resistant
polyclonal cells were selected and characterized. Three
different constructs of HBx were used to map the responsible
domain: full-length HBx (HBx-wt), HBx-D1, which lacks the
N-terminal negative regulatory domain, and HBx-D5, which
lacks the coactivation domain (Fig. 1a). First we examined HBx
expression in the primary human fibroblasts. We found that full-
length HBx and HBx-D5 were highly but equally expressed,
whereas expression of HBx-D1 was very weak in the blastcidin
S-selected clones (Fig. 1b). We hypothesized that HBx expres-
sion may confer an immortal phenotype, which could contribute
to cellular transformation and tumorigenesis, but we observed
that the BJ cells expressing HBx proteins stopped dividing at
PD 69.6 ± 0.9 (errors ± SD) (HBx-wt), PD 66.6 ± 1.6 (HBx-D5),
PD 66.1 ± 1.4 (HBx-D1) and PD 60.5 ± 0.6 (control cells)
(Fig. 1c). TIG3 cells, another human fibroblast, expressing HBx
proteins stopped dividing at PD 77.2 ± 1.1 (HBx-wt), PD 75.1 ± 0.8
(HBx-D5), PD 75.1 ± 0.1 (HBx-D1) and PD 75.4 ± 0.2 (control
cells) (Fig. 1d). Although a very minor extended lifespan (2–
4 PD) was observed with HBx-wt-expressing primary human
fibroblasts, the HBx protein could not elicit immortalization. We
examined whether the effect of HBx on delay of cellular senes-
cence was correlated with putative augmentation of telomerase
activity in HBx-introduced BJ and TIG3 cells (Fig. 1e) as acti-
vation of the hTERT promoter was observed in hepatoma cell
lines that were transiently cotransfected with the HBx expression
vector and luciferase reporter vector of the hTERT promoter (S.
Murakami et al. unpublished data, 2005). Telomerase activity in
the extracts of cells expressing HBx-wt or HBx-D1 was slightly
higher than that of cells expressing empty vector or HBx-D5 in
both kinds of cells (Fig. 1e), but we failed to detect an increase
in hTERT protein expression (data not shown). Therefore, the
relevance of the weak augmentation of telomerase activity in the
HBx-expressing primary cells remains unclear.
Effect of HBx on immortalized BJ-hTERT cells. Next, we addressed
whether HBx facilitates the cellular transformation process
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using human immortal cells. For this purpose, we used BJ-
hTERT cells – these were BJ-derived cells immortalized by the
introduction of hTERT, as characterized previously.(19) HBx-wt
as well as its truncated mutants had no effect on cell
proliferation, telomerase activity or cell transformation. Using
the newly established TIG3-hTERT cells, we confirmed that the
stable expression of HBx, XD1 or XD5 did not affect cell
proliferation or cell transformation (data not shown). These
results indicate the inability of HBx alone to transform these
human immortalized cells.
Ability of HBx to overcome H-RASV12-induced senescence in BJ
cells immortalized by hTERT Seeing as HBx did not exhibit the
ability to immortalize primary human fibroblasts or to elicit
transformation into hTERT-induced immortal primary human
fibroblasts, we considered whether HBx functioned together with
an oncogene and induced cell transformation. Senescence induced
by active oncogene expression (OIS), such as oncogenic RAS,
is one of the anticancer processes in which tumor suppressors
and their related networks are involved, as demonstrated in vitro
and recently also in vivo.(31,32) Overcoming OIS is critical for
cellular transformation in vitro and cancerous cell proliferation
in vivo.(31) Therefore, we addressed whether HBx has a collaborating
role in transforming cells in the presence of oncogenic RAS or
in overcoming RAS-induced senescence.
To examine the effect of HBx on RAS-induced senescence-like
growth arrest, we introduced H-RASV12 into BJ-hTERT, BJ-
hTERT-HBx-wt, BJ-hTERT-HBx-D1 and BJ-hTERT-HBx-D5
cells using a retrovirus (Fig. 2d). BJ-hTERT cells expressing
H-RASV12 stopped proliferating within several days of RAS
introduction. In contrast, BJ-hTERT cells expressing both
H-RASV12 and HBx-wt (BJ-hTERT + H-RASV12 + HBx-wt)
continued to proliferate to more than 80 PD (Fig. 2a). Although
HBx-D1 also demonstrated the ability to overcome active
RAS-induced senescence, HBx-D5 failed to overcome OIS
(Fig. 2a). We also found that the growth rate of BJ-hTERT +
H-RASV12 + HBx-wt cells was much higher than that of BJ-
hTERT + H-RASV12 + HBx-D1 cells, probably reflecting the fact
that some portion of the latter cells were positive for SA-β-
gal (Fig. 2b,c). Consistent with this result, cells staining
positive for SA-β-gal were significantly fewer in BJ-hTERT +
Fig. 1. Hepatitis B virus protein X (HBx) can not immortalize human primary cells, but weakly affects cellular senescence and telomerase activity.
(a) Schematic representation of the HBx proteins.(5,8) The amino acids (aa) of full-length HBx (154 aa residues) and truncated HBx are shown. HBxD1
harbors the carboxy-terminal coactivation domain, spanning aa residues 51–154, whereas, HBxD5 harbors the amino-terminal negative regulatory
domain, spanning aa residues 1–50. (b) Expression of HBx, HBx-D1 and HBx-D5 proteins in infected BJ cells. Total cell lysates of BJ cells infected
with the empty vector (EV), human telomerase reverse transcriptase (hTERT), HBx, HBx-D1 and HBx-D5 expression retroviruses were fractionated
by sodium dodecylsulfate–polyacrylamide gel electrophoresis and subjected to western blot analysis with anti-FLAG M2 antibody. (c) Effect of HBx
on replicative senescence in BJ cells. BJ cells were infected with a control vector (filled circles) or hTERT (filled diamonds) and with a retrovirus
encoding wild-type HBx (filled squares), HBx-D1 (filled triangles) or HBx-D5 (open circles). Cells infected with pBabe-puro- and pBabe-blast were
selected with 1 µg/mL puromycin and 4 µg/mL blasticidin S, respectively. After 8 days of drug selection, triplicate samples of 1 × 105 cells were
plated and grown under normal conditions (day 0). (d) Effect of HBx mutants on replicative senescence in TIG3 cells. Symbols are the same as in
(c). (e) Telomerase activity in BJ cells as demonstrated by telomerase activity assay (TRAP). Total cell lysates (200 ng) prepared from BJ cells infected
with control vector, hTERT, HBx, HBx-D1, and HBx-D5 were subjected to TRAP assay using a TRAPEZE kit (Intergen).
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H-RASV12 + HBx-wt than in BJ-hTERT + H-RASV12 + HBx-D1
(Fig. 2c). These results indicate that HBx-wt has the ability to
overcome RAS-induced senescence. HBx-D1, the coactivator
domain of HBx, seems to be indispensable and sufficient for
overcoming RAS-induced senescence analyzed by the PD anal-
ysis, although HBx-D1 did not show the same ability as HBx-
wt. The incomplete ability of HBx-D1 may be due to the low
expression of HBx-D1 in the blastcidin S-selected clones in
BJ-hTERT cells, as observed with the BJ cells (see Discussion).
HBx protein is required for anchorage-independent growth
and tumor formation in nude mouse in response to H-RASV12.
HBx can overcome RAS-induced senescence (examined by the PD
analysis) and can indicate that HBx and RAS can induce cell
transformation. Therefore, we examined whether BJ-hTERT +
H-RASV12 + HBx-wt and BJ-hTERT + H-RASV12 + HBx-D1 cells
can form colonies in soft agar. We found that BJ-hTERT + H-
RASV12 + HBx-wt cells showed cell number-dependent formation
of colonies, which were much smaller size than those of control
cells, BJ-hTERT + H-RASV12 + SV40 LT + ST(20,33) (Fig. 3a,b).
In contrast, BJ-hTERT + H-RASV12 + HBx-D1 cells could not
form colonies in soft agar (Fig. 3a), although these cells overcame
RAS-induced senescence. This result strongly suggests that
HBx-D1 is not equivalent to HBx-wt in its ability to make
colonies in soft agar.
Next we tested the tumor-forming ability of BJ-hTERT +
H-RASV12 + HBx-wt or HBx-D1 cells in nude mice. BJ-
hTERT + H-RASV12 + HBx-wt cells were found to form tumors
in four of eight mice, although these tumors grew much more
slowly and were much smaller than those formed by BJ-
hTERT + H-RASV12 + SV40 LT + ST cells (eight of eight animals)
(Fig. 3c). In contrast, BJ-hTERT + H-RASV12 + HBx-D1 cells
did not generate tumors in nude mice (Fig. 3c), consistent with
the results of the soft-agar assay. These results indicate that
HBx contributes to cellular transformation by collaborating with
active RAS in human immortalized cells. To our knowledge,
this is the first report showing that HBx plays a critical role in
Fig. 2. Hepatitis B virus protein X (HBx) can overcome H-RASV12-induced cellular senescence of human immortalized cells. (a) Effect of HBx on H-
RASV12 induced senescence. BJ-human telomerase reverse transcriptase (hTERT) cells (open circles) and H-RASV12-induced BJ-hTERT-HBx-wt (filled
squares), BJ-hTERT-HBx-D1 (filled triangles), BJ-hTERT-HBx-D5 (filled diamonds) cells and BJ-hTERT-empty vector (EV) (cross) are shown. After
10 days of drug selection at population doubling (PD) 42, triplicate samples of 1 × 105 cells were plated and grown under normal conditions (day
0). (b) HBx overcomes H-RASV12-induced senescence of human immortalized cells. H-RASV12 and EV, full-length or truncated forms of HBx were
introduced into BJ-hTERT cells. Left panel shows photographs 10 days after infection of the H-RASV12-expression retrovirus. Right panels show
senescence-associated β-galactosidase (SA-β-Gal) staining 10 days after infection. (c) The percentage of cells positive for SA-β-Gal was determined
in BJ cells stably expressing HBx-wt, HBx-D1, HBx-D5 or empty vector, with or without H-RASV12 on day 9 after infection. Bars = mean ± SD. (d)
Western blot analysis of RAS-induced cells. Total cell lysates from BJ-hTERT cells stably expressing HBx-wt, HBx-D1, HBx-D5 or EV together with or
without H-RASV12 were prepared and fractionated by sodium dodecylsulfate–polyacrylamide gel electrophoresis, then subjected to western blot
analysis. HBx-wt, HBx-D1 and HBx-D5 were detected with anti-FLAG M2 antibody. RAS protein was detected with anti-RAS antibody.
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cellular transformation, collaborating with active RAS in human
immortalized cells.
Effects of HBx on p16 and p21 expression and the ability of HBx to
overcome RAS-induced senescence. Overexpression of RAS causes
oncogene-induced premature senescence in normal human
fibroblasts (Fig. 4c) and hTERT-immortalized human fibroblasts
(Fig. 2a), but RAS failed to induce premature senescence in
HBx-wt- or HBx-D1-introduced BJ-hTERT cells (Fig. 2a). We
next examined the effect of stable expression of HBx in BJ cells
with or without expression of hTERT, as interference with both
the p53 and pRb pathways is necessary to avoid RAS-induced
cellular senescence, in which p16 and p21 are the critical
downstream effectors of pRb and p53, respectively. Expression
of p16 and p21 was upregulated in HBx-wt- or HBx-D1-
introduced BJ-hTERT cells; however, HBx-D5 has no ability to
induce the expression of these genes. The presence of H-RASV12
resulted in downregulation of the augmented expression of p16
and p21 in HBx-wt- or HBx-D1-introduced BJ cells and BJ-
hTERT cells (Fig. 4a,b). These results suggest that HBx can
suppress expression of p53, p16 and p21 in H-RASV12-introduced
cells, contributing to overcoming RAS-induced senescence. Next
we examined whether HBx-wt and H-RASV12 not immortalized
by hTERT were sufficient for cellular transformation. We
introduced H-RASV12 into BJ-HBx-wt, BJ-HBx-D1 and BJ-HBx-
D5 cells and analyzed them by PD analysis and soft-agar colony
assay. In the PD analysis, H-RASV12-introduced BJ-HBx-wt and
BJ-HBx-D1 cells did overcome RAS-induced cellular senescence
but stopped cell division at PD 62, which is approximately the
cellular senescence of BJ cells (Figs 1c,4c), whereas H-RASV12-
introduced BJ-HBx-D5 did not overcome senescence and
stopped cell division. These results suggest that HBx can overcome
RAS-induced senescence but can not immortalize the cells (Fig. 4c).
In the soft-agar colony formation assay, BJ-HBx-wt-H-RASV12
and BJ-HBx-D1-H-RASV12 could but BJ-HBx-D5-H-RASV12
could not form very tiny colonies, suggesting that HBx-wt and
H-RASV12 in the absence of hTERT may enable the cells to
proliferate in an anchorage-independent manner (data not shown).
As HBx-D1, which was very weakly expressed, exhibited
almost the same ability as HBx-wt to upregulate the tumor
suppressor genes and to overcome RAS-induced senescence in
these cells, we wondered whether HBx-D1 missing the N-terminal
domain may have some negative effect on cell proliferation.
Because the transient expression level of HBx-D1 in BJ cells









Fig. 3 (a,b) Anchorage-independent growth in soft agar and (c) tumorigenicity and tumor-forming ability in nude mice of cells expressing
hepatitis B virus X protein (HBx) and H-RASV12. (a) Soft-agar assays were carried out as described in Materials and Methods.(19) After 3 weeks,
colonies were counted and pictures were taken. The colony-forming ability of BJ-human telomerase reverse transcriptase (hTERT) cells stably
expressing wild-type or truncated HBx with or without H-RASV12 is indicated at the bottom. H-RASV12-introduced BJ-hTERT-LT-ST cells were the
positive control. (b) Morphology of colonies in the soft-agar assay. Colonies were photographed 21 days after seeding. (c) Tumor formation in
nude mice was carried out as described previously in Materials and Methods.(19,21) Tumor sizes were measured once a week. Each point on the
graph represents the average volume of tumors. BJ-hTERT-LT-ST-RAS (filled diamonds), BJ-hTERT-HBx-RAS (filled squares), BJ-hTERT-HBx-D1 (filled
circles), and BJ-hTERT (filled triangles) cells are shown. Error bars indicate the mean ± SD for each time point.
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(Fig. 4d),(8) it was not due to the construct design of the vector.
The expression of HBx-D1 was slightly lower than those of
HBx-wt and HBx-D5 on day 5 after selection, much lower on
day 10 after selection (data not shown). On day 14 after selec-
tion, the expression of HBx-D1 reached the lowest level, and
after day 14 that expression level was kept (Figs 1b,4d). HBx-
D1-introduced BJ cells grew slower than HBx-wt- or HBx-
D5-introduced BJ cells (data not shown) and contained more
SA-β-Gal-positive cells during proliferation (Fig. 4e). These results
suggest that cells expressing lower levels of HBx-D1 proliferated
more than cells expressing higher levels of HBx-D1, due to
some toxic or antiproliferative effect of the coactivation domain
of HBx in the human primary cells (see Discussion).
Important region of HBx for overcoming cellular senescence and
anchorage-independent growth. As HBx exhibited the ability to
overcome active RAS-induced senescence, we next tried to
identify the critical regions of HBx for overcoming cellular
senescence. BJ-hTERT cells were infected with retroviruses
expressing one of the clustered alanine-substituted mutants
covering all parts of HBx,(34) and a series of cell clones stably
expressing these HBx-cm mutants, BJ-hTERT-HBx-cm, was
established (Fig. 5). H-RASV12 was then introduced into BJ-
hTERT-HBx-cm1 to BJ-hTERT-HBx-cm21 cells and cell
proliferation was examined. The regions covering HBx-cm8 to
HBx-cm10, and those covering HBx-cm19 to HBx-cm21 were
found to be not critical for overcoming active RAS-induced
senescence and anchorage-independent growth as the BJ-
hTERT-RAS clones expressing these HBx-cm mutants proliferated
and formed colonies in soft agar, similar to BJ-hTERT-HBx-
wt-H-RASV12 cells. The BJ-hTERT-RAS clones expressing
HBx-cm1 to HBx-cm7, and those expressing HBx-cm14 to HBx-
cm16, were like BJ-hTERT-HBx-D1-RAS, which can grow but at
a much reduced rate compared with BJ-hTERT-HBx-RAS cells.
The HBx regions covering HBx-cm11 to HBx-cm13, HBx-cm17
Fig. 4. Effect of hepatitis B virus X protein (HBx) on p16 and p21 expression and the ability of HBx to overcome H-RASV12-induced cellular
senescence of human normal cells. Total cell lysates from BJ-human telomerase reverse transcriptase (hTERT) cells stably expressing HBx-wt, HBx-
D1, HBx-D5 or empty vector together with or without H-RASV12 were prepared, and fractionated by sodium dodecylsulfate–polyacrylamide gel
electrophoresis (SDS-PAGE), then subjected to western blot analysis. Expression of (a) p16 and p21 proteins and (b) p53, p16 and p21 proteins.
(c) Effect of HBx on H-RASV12-induced senescence. Population doublings (PD) of H-RASV12-induced BJ-HBx-wt (filled squares), BJ-HBx-D1 (filled
triangles), BJ-HBx-D5 (open diamonds) and BJ-EV (cross) cells are shown. After 10 days of drug selection, at PD 44, triplicate samples of 1 × 105 cells
were plated and grown under normal conditions (day 0). (d) Expression of HBx, HBx-D1 and HBx-D5 proteins in infected BJ cells. Total cell lysates
of BJ cells transfected with mammalian expression plasmids of FLAG-HBx-wt, FLAG-HBx-D1 and FLAG-HBx-D5 were fractionated by SDS-PAGE and
subjected to western blot analysis with anti-FLAG M2 antibody (upper panel). Total cell lysates of BJ cells infected with the empty vector (EV), HBx-
wt, HBx-D1 and HBx-D5 expression retroviruses were fractionated by SDS-PAGE and subjected to western blot analysis with anti-FLAG M2 antibody
(middle and bottom panel). (e) The percentage of cells positive for senescence-associated β-galactosidase (SA-β-Gal) was determined in BJ cells
stably expressing HBx-wt, HBx-D1, HBx-D5 or empty vector (EV) on day 40 after infection. Bars = mean ± SD.
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and HBx-cm18 were found to be critical for overcoming active
RAS-induced senescence as the BJ-hTERT-RAS clones express-
ing these HBx-cm mutants failed to proliferate, meaning that
these had no ability to overcome active RAS-induced cellular senes-
cence at all (Fig. 6) (Table 1). Among the BJ-hTERT-HBx-cm
cells, expression levels of HBx-cm1 to HBx-cm6 were very
weak, like that of HBx-D1. Furthermore, the protein bands of
HBx-cm1 to HBx-cm5 migrated slightly slower than those of
HBx-cm6 and the other HBx-cm mutants in the coactivation
domain in SDS-PAGE analysis (see Discussion).
Fig. 5. Expression of hepatitis B virus X protein
(HBx) library of clustered alanine substitution
mutants in BJ-human telomerase reverse transcriptase
(hTERT) cells. (a) Schematic representations of a
series of clustered alanine substitution mutants
(cm1 to cm21) of HBx. The amino acid locations of
the clustered mutations are shown. (b) Detection
of the mutated HBx proteins. Total cell lysates
prepared from BJ-hTERT cells transfected with the
mutant HBx expression vectors were fractionated
by sodium dodecylsulfate–polyacrylamide gel
electrophoresis and subjected to western blot
analysis with anti-FLAG M2 antibody.
Fig. 6. Critical regions of hepatitis B virus X protein (HBx)-wt for tumorigenic function. (a) Effect of HBx-cm1–7 and HBx-cm11–18 failed to
overcome H-RASV12-induced cellular senescence. Cell proliferation curves of several HBx-cm clones introduced with BJ-human telomerase reverse
transcriptase (hTERT)-H-RASV(12) in addition to those of BJ-hTERT cells (filled diamonds), H-RASV12-introduced BJ-hTERT-HBx-wt cells (filled squares)
and BJ-hTERT-HBx-D1 cells (filled triangles) are shown. HBx-cm1, -cm7, -cm12, -cm14 and -cm17 were selected. HBx-cm1 (closed circles) and HBx-
cm7 (open diamonds) represent HBx-cm1–7-introduced BJ-hTERT-H-RASV12 cells. HBx-cm12 (open triangles) represents HBx-cm11–13-introduced BJ-
hTERT-H-RASV12 cells. HBx-cm14 (open squares) represents HBx-cm14–16-introduced BJ-hTERT-H-RASV12 cells. HBx-cm17 (open circles) represents
HBx-cm17 and HBx-cm18-introduced BJ-hTERT-H-RASV12 cells. pBabe-puro-RAS-infected cells were selected with 1 µg/mL puromycin. After 10 days
of drug selection at population doubling (PD) 44, triplicate samples of 1 × 105 cells were plated and grown under normal conditions. (b) Effect of
HBx-cm8–10 and HBx-cm19–21 overcomes H-RASV12-induced cellular senescence. Cell proliferation curves of several HBx-cm clones introduced into
BJ-hTERT-H-RASV12 in addition to those of BJ-hTERT cells (filled diamonds), H-RASV12-introduced BJ-hTERT-HBx-wt cells (filled square) and BJ-hTERT-
HBx-D1 cells (filled triangles) are shown. HBx-cm8 (open squares) and HBx-cm10 (open triangles) represent HBx-cm8–10-introduced BJ-hTERT-H-
RASV12 cells. HBx-cm20 (open diamonds) represents HBx-cm19–21-introduced BJ-hTERT-H-RASV12 cells.
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Discussion
Hepatitis B virus X protein has long been suspected to be
positively involved in HBV-associated HCC, but its molecular
role in hepatocarcinogenesis remains unclear. Although HBx is
involved directly in the transformation of immortal rodent
cells in vitro and in tumor formation in the livers of nude mice,
the oncogenic activity of HBx itself remains to be elicited as
the reproducibility of these experiments has been seriously
controversial.(5) Furthermore, the positive role of HBx has not
been addressed with human primary cells or human immortal
cells. To our knowledge, our report is the first to show that
HBx retains the ability to overcome RAS-induced senescence
of immortalized human cells, although it is not sufficient
for immortalizing human primary cells or transforming human
immortal cells. hTERT-immortalized human cells stably expressing
HBx-wt and RAS can form colonies in soft agar and tumors in
nude mice in a cell-number-dependent manner. HBx can overcome
RAS-induced senescence of BJ cells, but HBx-wt and active
RAS could not immortalize the human fibroblasts. Although our
findings are different to a report showing that HBx itself retains
the transforming ability in NIH3T3 cells,(9) they are similar to
results in rodent immortal embryonic fibroblast cells.(10)
To determine the region of HBx responsible for the ability to
overcome RAS-induced senescence, we used two truncation
mutants: HBx-D1 (aa 51–154), which exhibits transcriptional
coactivation function and augments HBV transcription and rep-
lication,(8) and HBx-D5 (aa 1–50), which harbors the negative
regulatory domain of transcriptional modulation.(6) When HBx-
D1 and H-RASV12 were introduced into BJ-hTERT cells,
HBx-D1 was similar to wild-type HBx in overcoming RAS-
induced senescence in the PD analysis and in SA-β-gal staining.
Therefore, HBx-D1 alone seems to be sufficient for overcoming
active RAS-induced senescence and for anchorage-independent
growth, but it is not sufficient for BJ-hTERT + H-RASV12 +
HBx-D1 cells to form visible colonies in soft agar and tumors
in nude mice. HBx alone may be sufficient for overcoming
RAS-induced senescence, but hTERT is required for immortal
proliferation of the transformed cells with H-RASV12 and HBx.
As HBx-D1 exhibits a similar ability to HBx-wt in overcoming
RAS-induced senescence and anchorage-independent growth, but
not in immortalizing human fibroblasts, HBx-D1 may harbor all
of the critical abilities of HBx. However, HBx-D1 is different
from HBx-wt in the ability to form visible colonies in soft agar
and to form tumors in nude mice.
The coactivation function was recently mapped by scanning a
HBx library of clustered alanine substitution mutants (HBx-cm
library), and two separate sequences in HBx-D1 were found
to be critical.(8) Using the same HBx-cm library, we attempted
to map the sequences critical for overcoming RAS-induced
senescence. We have identified three different phenotypes
among the HBx-cm mutants: those phenotypes are like HBx-wt,
HBx-D1 and HBx-D5 (Fig. 6). HBx-cm mutations within the
D5 region, cm1 to cm7, have the ability to partially overcome
OIS, whereas those within the D1 region (cm8–10, cm14–16
and cm 19–21) fail to exhibit the overcoming ability. The
HBx-D5 phenotype is even found among the HBx-cm mutants
(cm13, cm17 and cm18) that are defective in the coactivation
function.(8) These results indicate that the ability to fully over-
come OIS requires two putative functions carried by the D1 and
D5 regions of the HBx protein. Because HBx-D5 does not have
a positive or negative effect on RAS-induced senescence
(Figs 2,3,4c), the negative regulatory domain may be active only
in full-length HBx. The very low expression of HBx-D1 in
human primary cells and hTERT-immortalized cells may be due
to the selection result of clones, reflecting that a high level
of HBx-D1 protein was eliminated due to a toxic effect of
the coactivation domain,(5) or due to deletion of the N-terminal
domain that has some critical role in stabilizing HBx in the
expression system. Both of these may actually occur. The
former is supported by the enrichment of cells expressing HBx-
D1 during the early stages of drug selection. The latter is highly
possible as expression levels of HBx-cm1 to HBx-cm6 covering
most of the N-terminal domain were very low, as for HBx-D1.
Pang et al. recently reported a stabilization mechanism of
HBx through direct interaction with Pin1,(35) which binds
phosphorylated serine and the next proline. The target serine
residue is within the N-terminal domain or within the region
covered by HBx-cm6. Interestingly, the HBx-cm1 to HBx-cm5
bands migrated more slowly than the HBx-cm6 band (Fig. 5b),
supporting the possibility that the N-terminal domain may be
critical for Pin1 binding to stabilize HBx. One interesting possi-
bility that remains to be tested is that activation of the degrada-
tion pathway of HBx causes the toxic effect on cell
proliferation. This possibility may explain the low expression of
HBx-D1 and the cm mutants in the N-terminal domain. In this
context, it remains unclear at present the reason for the rather
stable expression of two bands of HBx-cm7 that seem to confer
the same phenotype as HBx-D1 in the characterization of the cells.
The region of D1 that is responsible for overcoming RAS-
induced senescence should be defined. Because some HBx-cm
mutants defective in coactivation function still exhibit the ability
to overcome OIS, it seems that the coactivation function is dis-
pensable for the role. More than a dozen host factors have been
reported to interact directly with the HBx-D1 region, including
p53,(36,37) Smad4,(38) DDB1,(39,40) and two core subunits of the
proteasome.(5) It is especially important to determine whether
the binding of HBx to p53 is responsible for the ability to overcome
RAS-induced senescence, as the direct binding of p53 to HBx
was found to suppress p53-dependent gene activation.(5,37)
Although we have shown here that the D5 region of HBx has
an indispensable biological role in anchorage-independent cell
growth, the critical role of the D5 region in overcoming OIS
remains obscure. The ability of the D5 region in full-length HBx


























†HBx-cm1–21 in this table represent HBx-cm1–21-introduced BJ-hTERT-
H-RASV12 cells. ‡Same as BJ-hTERT-HBx-D1-H-RASV12 cells. §Same as BJ-
hTERT-HBx-wt-H-RASV12 cells. ¶Senescence.
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to support anchorage-independent growth will provide a good
experimental system for revealing the function of the negative
regulatory domain of HBx, as no host factor has been reported
to interact specifically with the D5 region.
Our results clearly indicate that HBx retains the ability to
overcome RAS-induced senescence in human cells immortal-
ized by hTERT, although HBx alone could neither immortalize
nor transform human cells. The ability of HBx to collaborate
with active RAS in cell transformation may explain its role in
hepatocellular carcinogenesis. Our findings, however, were
obtained using an experimental model with immortalized cells
derived from human fibroblasts. Our results may not reflect the
role of HBx in HBV-infected liver, as overcoming the processes
of OIS seems to vary with tissue and tumor type.(41) The role of
HBx should therefore be addressed using human hepatocytes
and immortalized human hepatocytes. The former, however, are
quite difficult to obtain whereas the latter are available at
present. It had been immortalized by introducing the other viral
oncogene SV LT.(42,43)
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